Pharmacokinetic Interaction Between Isavuconazole and Rif...

연구 요약

Pharmacokinetic Interaction Between Isavuconazole and Rifabutin in a Real-World Setting.

Mycoses 학술지에 발표된 이 연구는 Shah S, Clarke L, Lee T 외 연구팀이 수행하였습니다.

핵심 내용

BACKGROUND: Since rifabutin has less severe drug interactions, it is preferred over rifampin when administered concomitantly with azole antifungals. However, limited data exist to evaluate this interaction. METHODS: This was a single-centre study of hospitalised patients who received concomitant isavuconazole and rifabutin prior to plasma isavuconazole therapeutic drug monitoring. Isavuconazole was administered at a standard dose of isavuconazonium sulphate 372 mg every 8 h for six doses followed by 372 mg every 24 h. RESULTS: Of the seven patients included, the median age (range) was 53 years (33-67), 71% (5/7) were solid organ transplant recipients and no patients had underlying cirrhosis. The median (range) corrected 24-h steady-state isavuconazole was 2.7 mg/L (0.7-3.7) and 86% (6/7) had an isavuconazole level > 1 mg/L. The median (range) area under the curve (AUC 24), half-life (T CONCLUSION: This study demonstrates that isavuconazole trough concentrations are often maintained above 1 mg/L despite patients being on concomitant rifabutin. However, therapeutic drug monitoring is mandatory in this setting. Further research is warranted to confirm these results.

일반인을 위한 해석

이 연구는 약물 또는 영양제의 안전한 사용에 관한 과학적 근거를 제공할 수 있습니다. 다만, 개별 연구 결과만으로 일반화하기는 어려우며, 추가적인 연구가 필요할 수 있습니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41574599)